- Tositumomab
drugbox
type = mab
source = Mouse
target = CD20
CAS_number = 192391-48-3
ATC_prefix = V10
ATC_suffix = XA53
ATC_supplemental =
PubChem =
DrugBank = BTD00085
C=6416 | H=9874 | N=1688 | O=1987 | S=44
molecular_weight = 143859.7 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Tositumomab is a
monoclonal antibody derived from immortalized mouse cells. It is aIgG 2a anti-CD20 antibody and is covalently bound to 131I. 131I emits both beta andgamma radiation and decays with ahalf-life of 8 days.Clinical trials have established the efficacy of tositumomab in patients with relapsed or
chemotherapy /rituxan refractory follicular lymphoma .The drug was developed by Dr. Mark Kaminski and Dr. Richard Wahl. It is manufactured by
Corixa . It sells in the U.S. under the trade name Bexxar.There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.cite journal |author=Jacene HA, Filice R, Kasecamp W, Wahl RL |title=Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice |journal=
J. Nucl. Med. |volume=48 |issue=11 |pages=1767–76 |year=2007 |pmid=17942813 |doi=10.2967/jnumed.107.043489 |url=http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=17942813]References
Wikimedia Foundation. 2010.